Evidence map›Paper›PMID 25720821›Full record

ArticleJournal of pharmaceutical and biomedical analysis2015

N-acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administration.

Robert D Winefield, Anthonius A M Heemskerk, Swetha Kaul, Todd D Williams, Michael J Caspers, Thomas E Prisinzano, Elinore F McCance-Katz, Craig E Lunte, Morris D Faiman

Open access · bronzeAbstract read
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Robert D WinefieldMass Spectrometry Laboratory, University of Kansas, Lawrence, KS 66045, USA. Electronic address: rwinefield@kumc.edu.
Anthonius A M HeemskerkDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Swetha KaulRalph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Todd D WilliamsMass Spectrometry Laboratory, University of Kansas, Lawrence, KS 66045, USA.
Michael J CaspersDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Thomas E PrisinzanoDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Elinore F McCance-KatzDepartment of Psychiatry, University of California, San Francisco, San Francisco, CA 94143, USA.
Craig E LunteDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Morris D FaimanDepartment of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045, USA.
University of Kansas · USUniversity of California, San Francisco · US

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI John A Stanford · 2012 to 2026
$63.0M
Disulfiram Interactions With HIV Medications: Clinical ImplicationsR01DA024982 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCANCE-KATZ, ELINORE F. · 2008 to 2010
$1.4M
Role of Buprenorphine in Improving Clinical Care in Opioid Addiction and HIVK24DA023359 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCANCE-KATZ, ELINORE F. · 2007 to 2011
$918k
Carbamathione, A Novel Disulfiram Metabolite for Cocaine DependenceR21DA021727 · NIDA · UNIVERSITY OF KANSAS LAWRENCE · PI FAIMAN, MORRIS DAVID · 2008 to 2009
$396k
NIDA NIH HHS DA 021727NIDA NIH HHS DA 023359NIDA NIH HHS DA 024982NIDA NIH HHS K24 DA023359NIDA NIH HHS R01 DA024982NIDA NIH HHS R21 DA021727NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20GM103418
6 · The paper itself

Abstract

Disulfiram (DSF), a treatment for alcohol use disorders, has shown some clinical effectiveness in treating addiction to cocaine, nicotine, and pathological gambling. The mechanism of action of DSF for treating these addictions is unclear but it is unlikely to involve the inhibition of liver aldehyde dehydrogenase (ALDH2). DSF is a pro-drug and forms a number of metabolites, one of which is N-acetyl-S-(N,N-diethylcarbamoyl) cysteine (DETC-NAC). Here we describe a LCMS/MS method on a QQQ type instrument to quantify DETC-NAC in plasma and intracellular fluid from mammalian brain. An internal standard, the N,N-di-isopropylcarbamoyl homolog (MIM: 291>128) is easily separable from DETC-NAC (MIM: 263>100) on C18 RP media with a methanol gradient. The method's linear range is 0.5-500 nM from plasma and dialysate salt solution with all precisions better than 10% RSD. DETC-NAC and internal standards were recovered at better than 95% from all matrices, perchloric acid precipitation (plasma) or formic acid addition (salt) and is stable in plasma or salt at low pH for up to 24 h. Stability is observed through three freeze-thaw cycles per day for 7 days. No HPLC peak area matrix effect was greater than 10%. A human plasma sample from a prior analysis for S-(N,N-diethylcarbamoyl) glutathione (CARB) was found to have DETC NAC as well. In other human plasma samples from 62.5 mg/d and 250 mg/d dosing, CARB concentration peaks at 0.3 and 4 nM at 3 h followed by DETC-NAC peaks of 11 and 70 nM 2 h later. Employing microdialysis sampling, DETC-NAC levels in the nucleus accumbens (NAc), medial prefrontal cortex (mPFC), and plasma of rats treated with DSF reached 1.1, 2.5 and 80 nM at 6h. The correlation between the appearance and long duration of DETC-NAC concentration in rat brain and the persistence of DSF-induced changes in neurotransmitters observed by Faiman et al. (Neuropharmacology, 2013, 75C, 95-105) is discussed.

Indexed as

AcetylcysteineAnimalsDisulfiramFemaleHumansMaleMicrodialysisNucleus AccumbensPrefrontal CortexProdrugsRatsRats, Sprague-DawleyThiocarbamatesAcetylcysteineDisulfiramN-acetyl-S-(N,N-diethylcarbamoyl)cysteineProdrugsThiocarbamatesCarbamathioneDETC-NACDisulfiramMercapturate pathwaySubstance abuse disorders

Identifiers

PMID25720821
PMCPMC4410022
OpenAlexW2007327553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.